Jiangsu Hengrui Pharmaceuticals, China's biggest drugmaker by market value, reported first-half net profit that was essentially flat, rising just 0.34% from a year earlier. The tepid result reflects the ongoing squeeze from China's volume-based procurement program, which has driven down prices for the company's older generic drugs even as its newer, innovative medicines continue to grow.
What's behind the numbers
For the six months through June, Hengrui's generics revenue fell 16.07% year-on-year to 5.1 billion yuan. The decline is a direct consequence of China's bulk-procurement scheme, where the state pools demand from hospitals and awards large contracts largely on price. That approach has been effective at cutting drug costs for patients, but it has compressed margins for off-patent medicines across the industry.
Hengrui has responded by deliberately scaling back investment in its generics business, according to management. Instead, the company is pivoting toward innovative drugs, a segment that grew 16.38% in the first half and now accounts for 63.16% of its pharmaceutical sales. That shift is part of a broader trend among Chinese drugmakers, which are increasingly focusing on research and development to offset the pricing pressure on older products.
Why this matters for investors
For everyday investors, Hengrui's results illustrate the trade-off many Chinese pharmaceutical companies face. The bulk-procurement program is a structural headwind for generics, but it also creates an incentive to develop new drugs that can command higher prices. Hengrui's innovative-drug growth suggests the strategy is working, but the overall profit picture remains muted because the generics decline is still weighing on the bottom line.
The company's experience is not unique. Other Chinese drugmakers have reported similar patterns, with generics revenue falling while innovative pipelines drive growth. Investors should watch how quickly Hengrui can transition its sales mix toward higher-margin products, and whether its R&D spending translates into new approvals and market share.
Hengrui's results also come amid a broader earnings season where companies are navigating mixed conditions. For instance, Europe's earnings season has strengthened, with profit forecasts climbing, while some consumer names like TJX have raised long-term outlooks but signaled softer near-term quarters. In Asia, Hong Kong Exchanges posted a record first-half profit as IPO and trading activity rebounded, showing that market conditions can vary widely by sector and region.
What to watch next
Investors will likely focus on Hengrui's ability to sustain innovative-drug growth and whether it can offset further generics declines. The company's pipeline and any new drug approvals will be key indicators. Also worth watching is how the bulk-procurement program evolves, as any changes to its scope or pricing rules could affect the entire sector.
For now, Hengrui's flat profit growth underscores the challenges of operating in China's drug market, but also the potential rewards for companies that successfully pivot to innovation. As always, investors should consider their own risk tolerance and diversification when evaluating exposure to such names.
